MetaCap

MaxCyte Financial Statements

NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD

1.37+0.09 (+7.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MaxCyte revenue and earnings

In fiscal 2025, MaxCyte generated $33.0 million in revenue, down 14.5% from fiscal 2024, its first annual decline since 2024. MaxCyte reported a net loss of $44.6 million, compared with a loss of $41.1 million a year earlier. Gross margin was 81.2% (down from 81.6%) and operating margin -157.1%.

Diluted earnings per share came in at -$0.42. Over the last 5 fiscal years, MXCT's revenue has grown at a 4.8% compound annual rate.

Summary generated from market data by MetaCap's automated system. Methodology

MaxCyte income statement (annual)

MaxCyte annual income statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31
Revenue33.03M38.63M41.29M44.26M33.89M26.17M21.62M
Revenue growth (YoY)-14.50%-6.44%-6.72%+30.59%+29.52%+21.04%—
Cost of Revenue6.22M7.10M4.74M5.10M3.65M2.77M2.50M
Gross Profit26.80M31.53M36.55M39.16M30.25M23.40M19.12M
Operating Expenses78.70M82.72M84.84M66.52M48.44M34.46M31.54M
Research & Development20.82M22.23M23.82M19.51M15.41M17.73M17.59M
Selling, General & Admin47.04M56.35M57.04M44.48M31.68M15.70M13.41M
Operating Income-51.90M-51.20M-48.30M-27.36M-18.19M-11.06M-12.42M
Interest Expense————5.40K21.70K51.90K
Other Income (Expense)7.27M10.14M10.38M3.79M-893.60K-759.70K-475.00K
Pretax Income-44.63M-41.05M-37.92M————
Income Tax————000
Net Income-44.63M-41.05M-37.92M-23.57M-19.08M-11.82M-12.89M
Net Income growth (YoY)———————
EPS (Basic)-0.42-0.39-0.37-0.23-0.21-0.17-0.23
EPS (Diluted)-0.42-0.39-0.37-0.23-0.21-0.17-0.23
Shares Outstanding (Basic)106.43M104.85M103.27M101.70M90.62M69.46M56.40M
Shares Outstanding (Diluted)106.43M104.85M103.27M101.70M90.62M69.46M56.40M
EBITDA-47.56M-46.88M-44.13M-24.66M-16.76M-10.01M-11.81M
Gross Margin81.16%81.62%88.51%88.48%89.24%89.43%88.44%
Operating Margin-157.14%-132.54%-116.98%-61.82%-53.66%-42.25%-57.44%
Net Margin-135.14%-106.29%-91.85%-53.25%-56.30%-45.15%-59.64%

This table shows 7 annual periods of MaxCyte's income statement, from FY 2025 back to FY 2019, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a income statement?

More financial data